Keri Yang, PhD

BeOne Medicines Ltd., USA

Poster(s):

• 1436 - Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line (1L) Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy in Chronic Lymphocytic Leukemia (CLL): Age-Related Disparity

• 1505 - A Meta-Analysis Investigating Response Rates of Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B-Cell Lymphomas

• 1528 - Estimating the Cardiac Deaths Associated with Treating Chronic Lymphocytic Leukemia with Ibrutinib versus Zanubrutinib in the United States

• 1908 - Number Needed to Treat Analyses of Zanubrutinib vs Acalabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

• 1909 - A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-naïve (TN) Chronic Lymphocytic Leukemia (CLL)

• 1910 - Comparative Efficacy of Zanubrutinib (ZANU) versus Fixed-Duration Acalabrutinib Plus Venetoclax (AV) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)

• 1911 - Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared-Decision Making